Publications by authors named "B C Lampson"
Purpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type ; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with high-risk aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with aberration.
Methods: This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by aberration (ClinicalTrials.
Patient-Reported Burden of Indolent Systemic Mastocytosis in a Managed Care Organization.
J Allergy Clin Immunol Pract
January 2025
Article Synopsis
- Indolent systemic mastocytosis (ISM) is the most common form of systemic mastocytosis, and its diagnostic challenges and impact on patients' lives need more examination.
- A survey of 40 adults with ISM revealed a lengthy diagnosis process, averaging over two years, with many patients experiencing severe symptoms that negatively affected their quality of life and work ability.
- The study found a strong correlation between symptom severity and physical/mental health scores, highlighting that those with moderate to severe symptoms suffered significantly more from skin and gastrointestinal issues compared to those with mild symptoms.
MASTering systemic mastocytosis: Lessons learned from a large patient cohort.
J Allergy Clin Immunol Glob
November 2024
Article Synopsis
- Systemic mastocytosis (SM) is a rare disease affecting about 32,000 people in the U.S., often misdiagnosed due to vague symptoms and the necessity for invasive tests.
- A study of 116 patients revealed that the majority had indolent SM, with a significant average delay of 58.3 months for diagnosis, and some patients progressed to more advanced forms.
- The findings emphasize the need for better awareness and understanding of SM to improve diagnosis and treatment, suggesting that further studies are necessary to establish effective follow-up care for patients.
Purpose: Germline missense variants of unknown significance in cancer-related genes are increasingly being identified with the expanding use of next-generation sequencing. The ataxia telangiectasia-mutated () gene on chromosome 11 has more than 1,000 germline missense variants of unknown significance and is a tumor suppressor. We aimed to determine if rare germline variants are more frequent in chronic lymphocytic leukemia (CLL) compared with other hematologic malignancies and if they influence the clinical characteristics of CLL.
View Article and Find Full Text PDF